Sign In
Buy COGT
$32.26
-0.500 (-1.53%)
At Close: Jun 03, 2026
Cogent Biosciences (COGT) Stock Soars 90% on Positive Clinical Data
03:08pm, Friday, 10'th Jun 2022
Today, investors in Cogent Biosciences and COGT stock have some promising clinical trial results to look at, as this stock soars. The post Cogent Biosciences (COGT) Stock Soars 90% on Positive Clinic
Cogent Biosciences to Host Investor Webcast on June 10, 2022 at 8:00am ET
10:15am, Monday, 06'th Jun 2022
– Event to review initial clinical data from APEX, a Phase 2 trial with bezuclastinib in Advanced Systemic Mastocytosis presented at European Hematology Association (EHA) Congress – Event to revie
Cogent Biosciences to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference
07:00am, Monday, 22'nd Nov 2021
CAMBRIDGE, Mass. and BOULDER, Colo.
Cogent Biosciences to Present Preclinical Data on Bezuclastinib at AACR-NCI-EORTC Conference
07:00am, Friday, 01'st Oct 2021
CAMBRIDGE, Mass. and BOULDER, Colo.
Cogent Biosciences Provides Corporate Updates and Reports Second Quarter 2021 Financial Results
07:00am, Monday, 16'th Aug 2021
CAMBRIDGE, Mass. and BOULDER, Colo.
Cogent Biosciences to Present at Ladenburg Thalmann Virtual Healthcare Conference 2021
07:00am, Tuesday, 29'th Jun 2021
CAMBRIDGE, Mass. and BOULDER, Colo.
Cogent Biosciences to Present at Jefferies Virtual Healthcare Conference 2021
07:00am, Wednesday, 26'th May 2021
CAMBRIDGE, Mass. and BOULDER, Colo.
Cogent Biosciences Provides Corporate Updates and Reports First Quarter 2021 Financial Results
07:00am, Wednesday, 12'th May 2021
CAMBRIDGE, Mass. and BOULDER, Colo.
Cogent Biosciences Reports Fourth Quarter 2020 and Full Year 2020 Financial Results
07:00am, Tuesday, 16'th Mar 2021
CAMBRIDGE, Mass., March 16, 2021 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today an
CAMBRIDGE, Mass., Dec. 4, 2020 /PRNewswire/ -- Cogent Biosciences, Inc. ("Cogent") (NASDAQ: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, t
Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock
11:08pm, Tuesday, 01'st Dec 2020
CAMBRIDGE, Mass., Dec. 1, 2020 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announ
Cogent Biosciences to Participate in 3rd Annual Evercore ISI HealthCONx Virtual Conference
07:00am, Friday, 20'th Nov 2020
CAMBRIDGE, Mass., Nov. 20, 2020 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today annou
Cogent Biosciences to Present at Jefferies 2020 Virtual London Healthcare Conference
04:30pm, Thursday, 12'th Nov 2020
CAMBRIDGE, Mass., Nov. 12, 2020 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today annou
Edited Transcript of COGT earnings conference call or presentation 12-Mar-20 8:30pm GMT
05:42am, Wednesday, 01'st Apr 2020
Q4 2019 Fluent Inc Earnings Call
Edited Transcript of COGT earnings conference call or presentation 11-Nov-19 9:30pm GMT
11:22pm, Wednesday, 13'th Nov 2019
Q3 2019 Fluent Inc Earnings Call
